Google
Trusted Resources: News & Events
Latest announcements and gatherings
Phase 1 trial to test under-the-skin injection of sevuparin in sickle cell patients
Modus Therapeutics is going to launch a Phase 1 clinical study in the United States to evaluate the potential of its lead candidate sevuparin for the treatment of sickle cell disease (SCD).
In the trial, the company will broaden the clinical scope and usefulness of sevuparin to treat sickle cell disease by testing its safety when administrated subcutaneously (under the skin).
This follows the acceptance by the U.S Food and Drug Administration (FDA) of an investigational new drug (IND) application for sevuparin.
Modus Therapeutics is currently evaluating the therapeutic activity of sevuparin to manage painful crisis, also known as acute vaso-occlusive crisis (VOC), in patients with sickle cell disease in an ongoing Phase 2 study (NCT02515838).
+myBinderRelated Content
-
Integration of neuropsychology services in a sickle cell clinic and subsequent healthcare use for pain crisesObjective: Growing literature has docum...
-
Orphan Drugs for Sickle Vaso-occlusion: Dawn of a New Era of Targeted TreatmentWhile an orphan disease in the USA, sick...
-
Vaso-Occlusive Pain Linked to Menstruation in Some Patients, Study FindsAcute vaso-occlusive pain is associated ...
-
Imara Reports Favorable Preclinical and Phase 1 Data on IMR-687 in Sickle Cell DiseaseImara Inc. today announced it will repor...
-
SCDAA Teams with MedicAlert Foundation to Improve Emergency Outcomes During Sickle Cell Crises[Hanover, Md., June 26, 2023] – The Si...
-
APS Scientific Meeting 2019The American Pain Society will hold its ...
-
Gamida Cell Announces $3.5 Million Grant from the Israeli GovernmentGamida Cell, a leader in cellular and im...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
